神经药理学报››2012,Vol. 2››Issue (2): 37-41.
王超,项国卿,洪浩
出版日期:
2012-04-26发布日期:
2013-11-01通讯作者:
洪浩,男,副教授,博士,硕士生导师;研究方向:神经药理;Tel:+86-025-86185227,E-mail:haohongchina@hotmail.com基金资助:
国家自然科学基金资助项目(No.81273497),国家“重大新药创制”科技重大专项资助项目(No.2012ZX09103-101-007)
WANG Chao,XIANG Guo-qing,HONG Hao
Online:
2012-04-26Published:
2013-11-01Contact:
洪浩,男,副教授,博士,硕士生导师;研究方向:神经药理;Tel:+86-025-86185227,E-mail:haohongchina@hotmail.comSupported by:
国家自然科学基金资助项目(No.81273497),国家“重大新药创制”科技重大专项资助项目(No.2012ZX09103-101-007)
摘要:阿尔茨海默病(Alzheimer's disease,AD)是全球共同关注的重大公共卫生课题和日益严重的社会问题,发掘防治AD的新靶标和新药物是当今医药领域亟待破解的难题。越来越多的研究显示,中枢肾素-血管紧张素系统(central rennin-angiotensin system,CRAS)与AD密切相关。本文根据相关文献报道,综述CRAS中血管紧张素II(angiotensin II,Ang II)及其受体(angiotensin II type 1 receptor,AT1R;angiotensin II type 2 receptor,AT2R),血管紧张素IV(angiotensin IV,Ang IV)及其受体(angiotensin II type 4 receptor,AT4R)以及血管紧张素转化酶(angiotensin converting enzyme,ACE)在AD发生发展中的作用,揭示可能成为防治AD的新靶标,提出开发新型抗AD药物的新思路。
中图分类号:
王超,项国卿,洪浩.中枢肾素-血管紧张素系统与阿尔茨海默病[J]. 神经药理学报, 2012, 2(2): 37-41.
WANG Chao,XIANG Guo-qing,HONG Hao.Central Rennin-angiotensin System and Alzheimer's Disease[J]. Acta Neuropharmacologica, 2012, 2(2): 37-41.
[1] Henry W Querfurth, Frank M LaFerla. Alzheimer's disease [J]. N Engl J Med, 2010, 362(4): 329-344. [2] Nathan Herrmann, Sarah A Chau, Ida Kircanski, et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review [J]. Drugs, 2011, 71(15): 2031-2065. [3] Martin Paul, Ali Poyan Mehr, Reinhold Kreutz. Physiology of local Renin-Angiotensin Systems [J]. Physiol Rev, 2006, 86(3): 747-803. [4] John W Wright, Joseph W Harding. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory [J]. Prog Neurobiol, 2004, 72(4): 263-293. [5] Unger T, Badoer E, Ganten D, et al. Brain angiotensin: Pathway and pharmacology [J]. Circulation, 1988, 77(6 Pt 2): 140-154. [6] Paul M, Printz M, Harns E. Loculation of renin and converting enzyme in nerve endings of rat [J]. Brain Res, 1985, 334(2): 315-322. [7] Victor J Dzau, Burt D W, Richard E Pratt. Molecular biology of the rennin angiotensin system [J]. Am J Physiol, 1988, 255(4): F563-573. [8] Victor J Dzau, Julie Ingelfinger, Richard E Pratt, et al. Identification of rennin and angiotensinogen messenger RNA sequences in mouse and rat brains [J]. Hypertension, 2009, 78(6):544-551. [9] Manwen Jim, Markus J Wilhelm, Rudolf E Lang. Endogenous tissure rennin-angiotensin systems From molecular biology to therapy [J]. Am J Med, 1988, 84(3A): 28-36. [10] Michael B Gutman, Douglas L Jones, John Ciriello. Effect of paraventricular nucleus lesions of drinking and pressor responses to ANG II [J]. Am J Physiol (Regul Intergr Conp Physiol), 1988, 255(6 Pt 2): 145-163. [11] Egemen Savaskan, Christoph Hock, Gianfranco Olivieri, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia [J]. Neurobiol Aging, 2011, 22(4): 541–546. [12] Savaskan E, Hochli M, Ganten D, et al. Angiotensin II immunoreactivity in the human striatum and hippocampus of elderly controls and patients with senile dementia of the Alzheimer type and multi-infarct dementia [J]. Dement Geriatr Cogn Disord, 1991, 2: 314–323. [13] Dimitri De Bundel, IIse Smolders, Patrick Vanderheyden, et al. Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy [J].CNS Neurosci Ther, 2009, 15(2): 315-339. [14] Zhu Dong-lin, Shi Jing-ping, Zhang Ying-dong, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats [J]. PLoS One, 2011, 6(1): e16037. [15] Li Nien-chen, Lee Austin, Whitmer Rachel, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis [J]. BMJ, 2010, 8(340): b5465. [16] Tobias V Lanz, Ding Zhao-qing, Peggy P Ho, et al. Angiotensin II sustains brain inflammation in mice via TGF- β [J]. J Clin Invest, 2010, 120(8): 2782–2794. [17] H Michael Tucker, Muthoni Kihiko-Ehmann, Sarah Wright, et al. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition [J]. J Neurochem, 2010, 75(5): 2172–2177. [18] John W Wright, Jospeh W Harding. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions [J]. Regul Pept, 1995, 59(3): 269-295. [19] Zhu Y Z, Chimon G N, Zhu Y C, et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats [J]. Neuroreport, 2000, 11(6): 1191-1194. [20] Li Jun, Juraj Culman, Heide Hortnagl, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury [J]. FASEB J, 2005, 19(6): 617-619. [21] Lutz Hein, Gregory S Barsh, Richard E Pratt, et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice [J]. Nature, 1995, 377(6551): 744-747. [22] Toshihiro Ichiki, Patricia A Labosky, Chiyo Shiota, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor [J]. Nature, 1995, 377(6551): 748-750. [23] Wang Jun, Lap Ho, Chen Ling-hong, et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease [J]. J Clin Invest, 2007, 117(11): 3393–3402. [24] Hajjar Ihab, Meaghan Hart, Chen Yu-ling, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial [J]. Arch Intern Med, 2012, 172(5): 442-448. [25] Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydroclorothiazide on cognitive function and quality of life in hypertensive patients [J]. Am J Hypertens, 1999, 12(11 Pt 1): 1130-1134. [26] Robert Fogari, Paola Preti, Amedeo Mugellini, et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients [J]. Am J Hypertens, 2002, 15(4): 36A. [27] Lusine Danielyan, Roman Klein, Leah R Hanson, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease [J]. Rejuvenation Res, 2010, 13(2-3): 195–201. [28] Emmanuelle Duron, Olivier Hanon. Antihypertensive treatments, cognitive decline, and dementia [J]. J Alzheimers Dis, 2010, 20(3): 903-914. [29] Jan Jozef Braszko, Anna Walesiuk, Przemyslaw Wielgat. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV [J]. J Renin Angiotensin Aldosterone Syst, 2006, 7(3): 168–174. [30] Davis CJ, Kramar EA, De A, et al. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation [J]. Neuroscience, 2006, 137(4): 1369–1379. [31] John W Wright, Eniko A Kramar, Elizabeth D Myers, et al. Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog [J]. Regul Pept, 2003, 113(1-3): 49–56. [32] Matthew L Hemming, Dannis J Selkoe. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor [J]. J Biol Chem, 2005, 280(450): 37644-37650. [33] John W Wright, Joseph W Harding. The brain angiotensin IV/AT4 receptor system as a new target for the treatment of Alzheimer's disease [J]. Drug Dev Res, 2010, 70(7): 472–480. [34] Alberto Arregui, Elaine K Perry, Martin Rossor, et al. Angiotensin converting enzyme in Alzheimer’s disease increased activity in caudate nucleus and cortical areas [J]. J Neurochem, 1982, 38(5): 1490–1492. [35] Dong Yi-Fei, Keiichiro Kataoka, Yoshiko Tokutomi, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease [J]. FASEB J, 2011, 25(9): 2911-2920. [36] Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels [J]. J Clin Invest, 1990, 86(4): 1343–1346. [37] Sergei Danilov, Francoise Savoie, Bertrand Lenoir, et al. Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large scale studies [J]. J Hypertens, 1996, 14(6): 719–727. [38] Roger Cox, Nourdine Bouzekri, Sabrina Martin, et al. Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides [J]. Hum Mol Genet, 2002, 11(23): 2969–2977. [39] Skidgel R A, Erdös E G. The broad substrate specificity of human angiotensin I converting enzyme [J]. Clin Exp Hypertens A, 1987, 9(2-3): 243-259. [40] Hu Jian-guo, Akira Igarashi, Makiko Kamata, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide(Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity [J]. J Biol Chem, 2007, 276(51): 47863-47868. [41] J Scott Miners, Zoe Van Helmond, Patrick G Kehoe, et al. Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme [J]. Brain Pathol, 2010, 20(4): 794–802. [42] Zou K, Yamaguchi H, Akaatsu H, et al. Angiotensin- enzyme converts amyloid-protein 1–42(Aβ1–42) to Aβ1–40, and its inhibition enhances brain Aβ deposition [J]. J Neurosci, 2007, 27(32): 8628–8635. [43] Elizabeth A Eckman, Stephanie K Adams, Frederick J Troendle, et al. Regulation of steady-state β -amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme [J]. J Biol Chem, 2006, 281(41): 30471-30478. [44] Hemming Matthew L, Selkoe Dennis J, Farris Wesley. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease [J]. Neurobiol Dis, 2007, 26(1): 273-281. [45] John W Wright, Joseph W Harding. The brain RAS and Alzheimer’s disease [J]. Exp Neurol, 2010, 223(2): 326–333. |
[1] | 谢彬, 黄志源, 林多朵, 杨福龙, 谢奕彬.针药结合干预阿尔茨海默病抑郁症状效果分析[J]. 神经药理学报, 2020, 10(5): 5-8. |
[2] | 赵雨薇, 甄艳杰, 戴月英, 沈丽霞.槲皮素对阿尔茨海默症神经保护作用研究[J]. 神经药理学报, 2020, 10(5): 55-64. |
[3] | 海吉涛, 罗焕敏.病原微生物与阿尔茨海默病相关性研究进展[J]. 神经药理学报, 2020, 10(4): 58-64. |
[4] | 杨旭华, 杜爽, 沈丽霞, 郝军荣.阿尔茨海默病的药物治疗研究进展[J]. 神经药理学报, 2020, 10(3): 47-53. |
[5] | 甄艳杰, 郭童林, 赵雨薇, 沈丽霞.植物雌激素介导线粒体途径对阿尔茨海默病神经保护作用的研究进展[J]. 神经药理学报, 2020, 10(1): 40-46. |
[6] | 杨琳,艾静.脑源雌激素在阿尔茨海默病中的作用研究进展[J]. 神经药理学报, 2019, 9(5): 50-64. |
[7] | 张帅,艾静.谷氨酸功能异常与阿尔茨海默病[J]. 神经药理学报, 2018, 8(6): 9-20. |
[8] | SHEN li-xia1,LIU Liang-liang1,ZHANG Ming1,LIU Yang1,ZHANG Dan-shen 2*.Research of Quercetin’s Estrogen-Like Action on Central Nervous System and Its Mechanisms[J]. 神经药理学报, 2018, 8(4): 23-25. |
[9] | 黄蕊,杨翠翠,张兰.二苯乙烯苷对APP/PS1 双转基因小鼠学习记忆及突触可塑性的影响[J]. 神经药理学报, 2018, 8(2): 31-31. |
[10] | 雷曦,王健辉,程肖蕊,张小锐,刘港,周文霞,张永祥.基于快速老化模型小鼠SAMP8 的CA-30 抗阿尔茨海默病的作用研究[J]. 神经药理学报, 2018, 8(2): 50-50. |
[11] | 王健辉,程肖蕊,张小锐,刘港,周文霞,张永祥.药物组合吲哚美辛与阿托伐他汀对阿尔茨海默病的治疗作用研究[J]. 神经药理学报, 2018, 8(2): 52-52. |
[12] | 王静,程肖蕊,周文霞,张永祥.快速老化模型小鼠海马囊泡谷氨酸转运体表达与兴奋性毒性关系的研究[J]. 神经药理学报, 2018, 8(2): 53-53. |
[13] | 张林,蒋宁,周文霞,张永祥.疾病特异性诱导性多功能干细胞AD 模型建立[J]. 神经药理学报, 2018, 8(2): 54-54. |
[14] | 郭鹏,张巍.阿尔茨海默病患者睡眠障碍及其与认知障碍关系的研究[J]. 神经药理学报, 2018, 8(2): 61-61. |
[15] | 连腾宏,李少武,余秋瑾,等.阿尔茨海默病伴发嗅觉障碍的临床特点及静息态功能核磁共振成像的研究[J]. 神经药理学报, 2018, 8(2): 62-62. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||